Translation of RG6102, an amyloid-targeting therapy with superior brain penetration properties, to the clinic

Several monoclonal antibodies have demonstrated positive impacts on clinical biomarkers of Alzheimer’s disease, however delivery of these molecules to the CNS is hampered by the blood-brain barrier. This presentation describes preclinical studies of RG6102, a novel construct comprising a TfR1-binding "brain shuttle" module linked to the anti-amyloid monoclonal antibody gantenerumab, which has been designed to facilitate transport of gantenerumab across the blood-brain barrier and improve its engagement with therapeutic targets in the brain. This presentation describes preclinical studies of RG6102 in mouse and cynomolgus monkey models, and the development of a PK/PD model to inform the design of first-in-human studies.